Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a neurotoxin presented as a sterile injectable for intramuscular use. It is employed to manage selected neuromuscular disorders by producing localized muscle paralysis, thereby reducing unwanted muscle activity in adult patients.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo, a botulinum toxin type A preparation, acts on the neuromuscular junction to modulate excessive muscle activity in several clinical settings. - Overactive bladder: reduces urinary urgency and frequency by relaxing detrusor muscle fibers. - Cervical dystonia: diminishes abnormal neck muscle contractions, improving head posture and pain. - Blepharospasm: lessens involuntary eyelid closure, enhancing visual function.

Adverse reactions may vary with injection site and patient characteristics.

Common Side Effects: - Injection site pain or bruising. - Localized muscle weakness. - Headache. - Dry mouth. - Transient dysphagia (when administered near neck muscles).

Serious or Rare Side Effects: - Spread of toxin effect causing generalized muscle weakness. - Respiratory compromise. - Severe allergic reaction (anaphylaxis). - Urinary retention. - Vision changes such as blurred vision.

Prior to administration, clinicians should assess patient history and potential risk factors. - Contraindication: Known hypersensitivity to botulinum toxin type A or any formulation component. - Caution: Use with caution in patients with neuromuscular disorders (e.g., myasthenia gravis). - Pregnancy: Safety not established; avoid unless clearly needed. - Breastfeeding: Limited data; weigh benefits against potential risks. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A may interact with agents that affect neuromuscular transmission.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin): may potentiate neuromuscular blockade. - Curare‑type muscle relaxants: increased risk of profound weakness.

Moderate Interactions (Monitor Closely): - Anticholinergic drugs: may modify therapeutic response. - Other botulinum toxin products: cumulative effect risk. - Calcium channel blockers: potential influence on muscle tone. - General anesthetics (e.g., succinylcholine): heightened sensitivity.